Febrile Seizure (FS): A seizure occurring in children aged 6 months to 5 years (some guidelines extend to 3 months or 6 years), associated with a temperature ≥38°C (100.4°F), not resulting from CNS infection, metabolic/electrolyte imbalance, or a history of prior afebrile seizures.
Explosive onset of refractory status epilepticus in older children (>5 years) following a febrile illness, often with poor neurologic outcomes.
III. ETIOPATHOGENESIS
Genetics: Often polygenic; 25–40% have a positive family history. Known single gene associations include SCN1A, SCN1B, and GABRG2.
Cytokines: Dysregulation between pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-1Ra) cytokines. IL-1β acts as both a pyrogen and an NMDA agonist.
Environmental: Associated with viral infections (HHV-6B, HHV-7, influenza, roseola), immunizations (DTP, MMR), and iron deficiency.
IV. CLINICAL EVALUATION
History: Focus on seizure semiology (focal vs. generalized), duration, fever onset, and post-ictal state. Assess family history and developmental status.
Examination: - Search for extracranial focus (Otitis media, pharyngitis, UTI).
Neurologic: Check for meningeal signs (Kernig’s/Brudzinski’s - unreliable <12 months), fontanelle tension, and focal deficits.
Red Flags: Persistent altered sensorium (>1 hour post-seizure), petechial rash, bulging fontanelle, or focal neurological signs.
V. INVESTIGATIONS
Lumbar Puncture (LP):
Mandatory: Clinical signs of meningitis (nuchal rigidity, etc.).
Consider: Infants 6–12 months if immunization status (Hib/Pneumococcal) is incomplete/unknown or if the child is on antibiotics (may mask signs).
Blood Studies: Not routine for simple FS. Check glucose if prolonged post-ictal state. Electrolytes indicated only if history of dehydration/vomiting.
Neuroimaging (CT/MRI): Not recommended for simple FS. Consider for complex FS with focal features or persistent neurologic abnormality.
EEG: Not predictive of recurrence or future epilepsy in simple FS. May be indicated in complex FS or if epilepsy is strongly suspected.
VI. MANAGEMENT
Acute Seizure Management:
Position in lateral decubitus, secure airway, monitor vitals.
If seizure >5 minutes:
IV Lorazepam (0.1 mg/kg) or IV Midazolam (0.1–0.2 mg/kg).
Alternatives: IM Midazolam (0.2 mg/kg) or Rectal Diazepam (0.3–0.5 mg/kg).
Fever Management: Antipyretics (Paracetamol 15 mg/kg or Ibuprofen 10 mg/kg) improve comfort but do not prevent FS recurrence.
Prophylaxis:
Continuous: Phenobarbital or Valproate generally not recommended due to side effects and lack of benefit in preventing future epilepsy.
Intermittent: For frequent recurrences or parental anxiety, oral Diazepam (0.3 mg/kg 8-hourly) or Clobazam may be given at the onset of fever for 48 hours.
Parental Counseling: Explain the benign nature, low mortality risk, and high recurrence rate. Provide a rescue medication plan.
VII. PROGNOSIS
Recurrence Risk of FS:
Overall: ~30%.
Risk Factors: Age <1 year, low degree of fever at onset, short duration of fever before seizure, and family history of FS.
Risk of Subsequent Epilepsy:
General Population: 0.5–1%.
Simple FS: 1–2%.
Complex FS: 5–10% (up to 30% if multiple risk factors like neurodevelopmental delay or focal features are present).